Product Code: RP-ID-10086135 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10086135
Market Overview:
Global Antiretroviral Drugs Market: Analysis By Drug Type (Multi-Class Drugs Combination Drugs, NRTI, NNRTI, Protease Inhibitors), By Region, By Country, Drug Forecast (2019 Edition): Opportunities and Forecast By Region (North America, Europe, APAC, ROW), By Country (U.S., Canada, Germany, U.K, France, Italy, China, Japan, India, South Africa) Outlook 2030
"The global antiretroviral drugs market is anticipated to expand at a CAGR of ~5% during the period 2022-2030. The market is segmented by drug category (integrase inhibitors, protease inhibitors, multiple types of combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, etc.) and geographic segments. Antiretroviral drugs are drugs used to treat HIV. Factors contributing to market growth include an increase in the burden of HIV, increased investment in research and development, and an increase in the supply of new drugs with better efficacy.
According to data from the U.S. Department of Health and Human Services, approximately 37.9 million people worldwide are infected with HIV/AIDS. In 2018, an estimated 1.7 million people worldwide were infected with HIV. Antiretroviral drugs (ARV) are the mainstay of HIV/AIDS treatment because there is currently no cure or vaccine available for HIV. For people with non-resistant HIV strains, antiretroviral therapy can inhibit about 80% of HIV replication. This large patient population indicates that the antiretroviral drug market is expected to grow during the forecast period.
REPORTING SCOPE :
According to the reporting scope, antiretroviral drugs are drugs used to treat retroviral infections, mainly HIV. Retroviruses are a group of viruses belonging to the Retroviridae family, which are characterized by carrying their genetic blueprint in the form of ribonucleic acid (RNA). Antiretroviral drugs make it harder for these viruses to reproduce rather than kill them.
MAIN MARKET TRENDS:
Multiple types of combination products are expected to achieve significant growth within the expected year. Based on drug categories, they are divided into integrase inhibitors, protease inhibitors, multiple types of combination products, transcriptase inhibitors, retro nucleoside analogs (NRTI), Nucleoside reverse transcriptase inhibitors (NNRTI) and so on. The key factors driving the growth of multiple types of combination products are the increase in the burden of HIV and the approval of new drugs. According to the World Health Organization, approximately 770,000 people died of HIV in 2018. Many companies are focusing on developing innovative products for the treatment of antiretroviral drugs to maintain their competitive advantage and enter new regional markets. In addition, increasing funding for companies involved in antiretroviral drug-related research is expected to promote the development of the research market.
NORTH AMERICA HAS THE LARGEST MARKET SHARE OF ANTIRETROVIRAL DRUGS:
The market for antiretroviral drugs has the largest share in North America. According to estimates by the U.S. Department of Health and Human Services, there are more than 56,000 new cases of HIV infection in the United States each year, and about 20 out of every 100 infected Americans do not know they are infected with the virus. This growth is attributable to the high coverage of ART and greater emphasis on branded prescription drugs. In addition, the National Institutes of Health (NIH) represents the worlds largest public investment in HIV/AIDS research and is expected to drive market growth.
COMPETITIVE LANDSCAPE :
The current needs of companies in the antiretroviral field are to enhance their R&D capabilities through cooperation, mergers and acquisitions, and exploring new geographic regions. Global players in the antiretroviral drug market include: AbbVie Inc., Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd, Gilead Sciences, Merck & Co, Inc., Mylan N.V. and ViiV Healthcare.
MAIN PALYERS:
Boehringer Ingelheim ,International Co., Ltd., Christol-Myers Squibb Company, Galaad Sciences, Inc., Merck & Co, Inc., ViV Healthcare. "
Gilead Sciences Inc., ViiV Healthcare, Bristol-Myers Squibb, AbbVie Inc., Boehringer Ingelheim, Johnson & Johnson, Merck & Co., Cipla, Mylan
Related Reports
Proof of Quality & Reliability
